Biopharma company Genticel receives €13.1m to treat cervical cancer

9 Mar 2010

French biopharmaceutical company Genticel, formerly known as BT Pharma, has secured €13.1m in funding to develop its immunotherapeutic treatments for cancers caused by the human pipillomavirus (HPV). Investors included IRDI, Amundi Private Equity Funds and InnoBio fund (CDC enterprises), in the round led by AGF Private Equity.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.

NEWS & VIEWS

Global private equity and venture capital news and research

By News Type

By PE Sector

By Region

By Region

Country Focus

PE Focus

Industry Focus

Other

AltAssets Events

Industry Events